$ALGS
Aligos Therapeutics, Inc.

2024 Q3 Form 10-Q Financial Statement

#000095017024122371 Filed on November 06, 2024

View on sec.gov

Income Statement

Concept 2024 Q3
Revenue $1.250M
YoY Change 15.21%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $4.626M
YoY Change -27.03%
% of Gross Profit
Research & Development $16.77M
YoY Change 5.72%
% of Gross Profit
Depreciation & Amortization $300.0K
YoY Change 0.0%
% of Gross Profit
Operating Expenses $21.40M
YoY Change -4.08%
Operating Profit -$20.13M
YoY Change 5.56%
Interest Expense $457.0K
YoY Change -54.75%
% of Operating Profit
Other Income/Expense, Net $506.0K
YoY Change 912.0%
Pretax Income -$19.17M
YoY Change 6.42%
Income Tax $91.00K
% Of Pretax Income
Net Earnings -$19.26M
YoY Change 6.75%
Net Earnings / Revenue -1540.72%
Basic Earnings Per Share -$3.07
Diluted Earnings Per Share -$3.07
COMMON SHARES
Basic Shares Outstanding 6.272M
Diluted Shares Outstanding 6.272M

Balance Sheet

Concept 2024 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $74.92M
YoY Change 6.42%
Cash & Equivalents $35.33M
Short-Term Investments $39.59M
Other Short-Term Assets $4.790M
YoY Change 15.7%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $79.82M
YoY Change 6.94%
LONG-TERM ASSETS
Property, Plant & Equipment $2.575M
YoY Change -29.37%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $635.0K
YoY Change 1.93%
Total Long-Term Assets $8.604M
YoY Change -23.24%
TOTAL ASSETS
Total Short-Term Assets $79.82M
Total Long-Term Assets $8.604M
Total Assets $88.43M
YoY Change 3.0%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $2.740M
YoY Change -6.83%
Accrued Expenses $14.16M
YoY Change 14.92%
Deferred Revenue
YoY Change
Short-Term Debt $0.00
YoY Change
Long-Term Debt Due $13.00K
YoY Change -87.0%
Total Short-Term Liabilities $20.96M
YoY Change -6.73%
LONG-TERM LIABILITIES
Long-Term Debt $188.0K
YoY Change -6.0%
Other Long-Term Liabilities $17.19M
YoY Change 104.6%
Total Long-Term Liabilities $17.37M
YoY Change 102.02%
TOTAL LIABILITIES
Total Short-Term Liabilities $20.96M
Total Long-Term Liabilities $17.37M
Total Liabilities $38.33M
YoY Change 23.52%
SHAREHOLDERS EQUITY
Retained Earnings -$535.9M
YoY Change 16.78%
Common Stock $585.4M
YoY Change 14.06%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $50.10M
YoY Change
Total Liabilities & Shareholders Equity $88.43M
YoY Change 3.0%

Cashflow Statement

Concept 2024 Q3
OPERATING ACTIVITIES
Net Income -$19.26M
YoY Change 6.75%
Depreciation, Depletion And Amortization $300.0K
YoY Change 0.0%
Cash From Operating Activities -$20.10M
YoY Change -1.18%
INVESTING ACTIVITIES
Capital Expenditures $26.00K
YoY Change 160.0%
Acquisitions
YoY Change
Other Investing Activities $10.42M
YoY Change
Cash From Investing Activities $10.40M
YoY Change -104080.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -4.000K
YoY Change -80.0%
NET CHANGE
Cash From Operating Activities -20.10M
Cash From Investing Activities 10.40M
Cash From Financing Activities -4.000K
Net Change In Cash -9.707M
YoY Change -52.35%
FREE CASH FLOW
Cash From Operating Activities -$20.10M
Capital Expenditures $26.00K
Free Cash Flow -$20.13M
YoY Change -1.1%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Entity Central Index Key
EntityCentralIndexKey
0001799448
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2024Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2024Q3 us-gaap Preferred Stock Value
PreferredStockValue
CY2023Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2024Q3 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
0.04
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2024-09-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-39617
dei Entity Registrant Name
EntityRegistrantName
Aligos Therapeutics, Inc.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
82-4724808
dei Entity Address Address Line1
EntityAddressAddressLine1
One Corporate Drive
dei Entity Address Address Line2
EntityAddressAddressLine2
2nd Floor
dei Entity Address City Or Town
EntityAddressCityOrTown
South San Francisco
dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
94080
dei City Area Code
CityAreaCode
800
dei Local Phone Number
LocalPhoneNumber
466-6059
dei Security12b Title
Security12bTitle
Common Stock, par value, $0.0001 per share
dei Trading Symbol
TradingSymbol
ALGS
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
false
dei Entity Shell Company
EntityShellCompany
false
CY2024Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
35331000
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
135704000
CY2024Q3 us-gaap Restricted Cash Current
RestrictedCashCurrent
110000
CY2023Q4 us-gaap Restricted Cash Current
RestrictedCashCurrent
70000
CY2024Q3 us-gaap Short Term Investments
ShortTermInvestments
39591000
CY2024Q3 us-gaap Other Assets Current
OtherAssetsCurrent
4790000
CY2023Q4 us-gaap Other Assets Current
OtherAssetsCurrent
5310000
CY2024Q3 us-gaap Assets Current
AssetsCurrent
79822000
CY2023Q4 us-gaap Assets Current
AssetsCurrent
141084000
CY2024Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
5394000
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
6559000
CY2024Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2575000
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
3259000
CY2024Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
635000
CY2023Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
625000
CY2024Q3 us-gaap Assets
Assets
88426000
CY2023Q4 us-gaap Assets
Assets
151527000
CY2024Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
2740000
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
2517000
CY2024Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
14161000
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
16842000
CY2024Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
3387000
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
3229000
CY2024Q3 us-gaap Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
13000
CY2023Q4 us-gaap Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
10000
CY2024Q3 algs Deferred Revenue From Customers Current
DeferredRevenueFromCustomersCurrent
655000
CY2023Q4 algs Deferred Revenue From Customers Current
DeferredRevenueFromCustomersCurrent
1224000
CY2023Q4 algs Deferred Revenue From Collaboration Current
DeferredRevenueFromCollaborationCurrent
84000
CY2024Q3 us-gaap Liabilities Current
LiabilitiesCurrent
20956000
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
23906000
CY2024Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
5545000
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
7668000
CY2024Q3 us-gaap Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
188000
CY2023Q4 us-gaap Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
231000
CY2024Q3 algs Warrant Liability Noncurrent
WarrantLiabilityNoncurrent
11595000
CY2023Q4 algs Warrant Liability Noncurrent
WarrantLiabilityNoncurrent
27596000
CY2024Q3 algs Long Term Liabilities Excluding Deferred Revenue
LongTermLiabilitiesExcludingDeferredRevenue
46000
CY2023Q4 algs Long Term Liabilities Excluding Deferred Revenue
LongTermLiabilitiesExcludingDeferredRevenue
46000
CY2024Q3 us-gaap Liabilities
Liabilities
38330000
CY2023Q4 us-gaap Liabilities
Liabilities
59447000
CY2024Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2024Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2024Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2024Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2024Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2024Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
20800000
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
12800000
CY2024Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
3324780
CY2024Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
3324780
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
3003855
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
3003855
CY2024Q3 us-gaap Common Stock Value
CommonStockValue
8000
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
7000
CY2024Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
585369000
CY2023Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
578325000
CY2024Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-535858000
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-486797000
CY2024Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
577000
CY2023Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
545000
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
50096000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
92080000
CY2024Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
88426000
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
151527000
CY2024Q3 us-gaap Revenue From Collaborative Arrangement Excluding Revenue From Contract With Customer
RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer
19000
CY2023Q3 us-gaap Revenue From Collaborative Arrangement Excluding Revenue From Contract With Customer
RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer
2154000
us-gaap Revenue From Collaborative Arrangement Excluding Revenue From Contract With Customer
RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer
311000
us-gaap Revenue From Collaborative Arrangement Excluding Revenue From Contract With Customer
RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer
7329000
CY2024Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
1250000
CY2023Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
1085000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
3005000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
5519000
CY2024Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
16774000
CY2023Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
15867000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
54238000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
50783000
CY2024Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4626000
CY2023Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
6443000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
17669000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
24195000
CY2024Q3 us-gaap Operating Expenses
OperatingExpenses
21400000
CY2023Q3 us-gaap Operating Expenses
OperatingExpenses
22310000
us-gaap Operating Expenses
OperatingExpenses
71907000
us-gaap Operating Expenses
OperatingExpenses
74978000
CY2024Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-20131000
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-19071000
us-gaap Operating Income Loss
OperatingIncomeLoss
-68591000
us-gaap Operating Income Loss
OperatingIncomeLoss
-62130000
CY2024Q3 us-gaap Other Operating Income Expense Net
OtherOperatingIncomeExpenseNet
963000
CY2023Q3 us-gaap Other Operating Income Expense Net
OtherOperatingIncomeExpenseNet
1059000
us-gaap Other Operating Income Expense Net
OtherOperatingIncomeExpenseNet
19834000
us-gaap Other Operating Income Expense Net
OtherOperatingIncomeExpenseNet
3168000
CY2024Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-19168000
CY2023Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-18012000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-48757000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-58962000
CY2024Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
91000
CY2023Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
29000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
304000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
825000
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-19259000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-18041000
us-gaap Net Income Loss
NetIncomeLoss
-49061000
us-gaap Net Income Loss
NetIncomeLoss
-59787000
CY2024Q3 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
83000
us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
32000
us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
96000
CY2024Q3 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
83000
us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
32000
us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
96000
CY2024Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-19176000
CY2023Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-18041000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-49029000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-59691000
CY2024Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-3.07
CY2024Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-3.07
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-10.37
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-10.37
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-7.84
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-7.84
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-34.59
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-34.59
CY2024Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
6272291
CY2024Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
6272291
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
1739847
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1739847
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
6258706
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
6258706
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
1728282
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1728282
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
67229000
CY2024Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Other Longterm Incentive Plans Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationOtherLongtermIncentivePlansRequisiteServicePeriodRecognition
1904000
CY2024Q3 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Employee Stock Purchase Program Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition
139000
CY2024Q3 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
83000
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-19259000
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
50096000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
92080000
us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
297000
algs Issuance Of Common Stock Upon Exercise Of Pre Funded Warrants Value
IssuanceOfCommonStockUponExerciseOfPreFundedWarrantsValue
1000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Other Longterm Incentive Plans Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationOtherLongtermIncentivePlansRequisiteServicePeriodRecognition
6321000
us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Employee Stock Purchase Program Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition
426000
us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
32000
us-gaap Net Income Loss
NetIncomeLoss
-49061000
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
50096000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
69635000
CY2023Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Other Longterm Incentive Plans Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationOtherLongtermIncentivePlansRequisiteServicePeriodRecognition
2883000
CY2023Q3 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Employee Stock Purchase Program Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition
326000
CY2023Q3 algs Vesting Of Early Excercised Common Stock Options Value
VestingOfEarlyExcercisedCommonStockOptionsValue
18000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-18041000
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
54821000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
103900000
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
23000
us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
461000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Other Longterm Incentive Plans Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationOtherLongtermIncentivePlansRequisiteServicePeriodRecognition
9361000
us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Employee Stock Purchase Program Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition
708000
algs Vesting Of Early Excercised Common Stock Options Value
VestingOfEarlyExcercisedCommonStockOptionsValue
59000
us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
96000
us-gaap Net Income Loss
NetIncomeLoss
-59787000
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
54821000
us-gaap Net Income Loss
NetIncomeLoss
-49061000
us-gaap Net Income Loss
NetIncomeLoss
-59787000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
1411000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
424000
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
1165000
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
1129000
us-gaap Operating Lease Impairment Loss
OperatingLeaseImpairmentLoss
724000
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-16001000
us-gaap Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
-17000
us-gaap Depreciation
Depreciation
786000
us-gaap Depreciation
Depreciation
1165000
us-gaap Share Based Compensation
ShareBasedCompensation
6747000
us-gaap Share Based Compensation
ShareBasedCompensation
10069000
us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
-512000
us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
-3472000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
223000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-1796000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-2681000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-3657000
algs Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-1966000
algs Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-1805000
us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
46000
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-84000
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-6650000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-569000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
1158000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-62340000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-56339000
us-gaap Proceeds From Sale Maturity And Collection Of Shortterm Investments
ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments
70000000
us-gaap Proceeds From Sale Maturity And Collection Of Shortterm Investments
ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments
45011000
us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
108149000
us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
11000
algs Purchases Write Offs Of Property And Equipment
PurchasesWriteOffsOfPropertyAndEquipment
-102000
algs Purchases Write Offs Of Property And Equipment
PurchasesWriteOffsOfPropertyAndEquipment
-12000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-38251000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
44988000
algs Proceeds From Issuance Of Common Stock Upon Exercise Of Pre Funded Warrants
ProceedsFromIssuanceOfCommonStockUponExerciseOfPreFundedWarrants
1000
us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
40000
us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
92000
us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
297000
us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
461000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
23000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
258000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
392000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-100333000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-10959000
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
135774000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
81462000
CY2024Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
35441000
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
70503000
CY2024Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
35331000
CY2023Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
70429000
CY2024Q3 us-gaap Restricted Cash
RestrictedCash
110000
CY2023Q3 us-gaap Restricted Cash
RestrictedCash
74000
CY2024Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
35441000
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
70503000
algs Market To Market Adjustments For Available For Sale Investments
MarketToMarketAdjustmentsForAvailableForSaleInvestments
32000
algs Market To Market Adjustments For Available For Sale Investments
MarketToMarketAdjustmentsForAvailableForSaleInvestments
96000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
1094000
algs Vesting Of Early Exercised Options Value
VestingOfEarlyExercisedOptionsValue
59000
us-gaap Nature Of Operations
NatureOfOperations
<div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">1.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Organization </span></div></div><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Description of business</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Aligos Therapeutics, Inc. (Aligos-US) was incorporated in the state of Delaware on February 5, 2018 (inception). On September 10, 2018, the Company formed Aligos Belgium BVBA (Aligos-Belgium), a limited liability company organized under the laws of Belgium. On March 30, 2020, the Company formed as a wholly owned subsidiary, Aligos Australia Pty LTD (Aligos-Australia), a proprietary limited company. On May 18, 2021, the Company formed as a wholly owned subsidiary, Aligos Therapeutics (Shanghai) Co. Ltd. (Aligos-Shanghai) and together with Aligos-US, Aligos-Belgium, and Aligos-Australia being the “Company” or “Aligos”.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Aligos is a clinical-stage biopharmaceutical company developing novel therapeutics to address unmet medical needs in viral and liver diseases, including for chronic hepatitis B (CHB), metabolic dysfunction associated steatohepatitis (MASH), and coronaviruses.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company is devoting substantially all of its efforts to the research and development of its drug candidates. The Company has not generated any product revenue to date. The Company is also subject to a number of risks similar to other companies in the biotechnology industry, including the uncertainty of success of its nonclinical studies and clinical trials, regulatory approval of drug candidates, uncertainty of market acceptance of products, competition from substitute products and larger companies, the need to obtain additional financing, compliance with government regulations, protection of proprietary technology, dependence on third-parties, product liability, and dependence on key individuals.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Liquidity</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company has incurred losses and negative cash flows from operations in each fiscal year since its inception. As of September 30, 2024 and December 31, 2023, the Company had an accumulated deficit of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">535.9</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">486.8</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, respectively. Management expects to continue to incur additional substantial losses in future fiscal years in the foreseeable future as a result of its research and development activities.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of September 30, 2024, the Company has cash, cash equivalents and investments of approximately </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">74.9</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> which is available to fund future operations. The Company expects to continue to spend substantial amounts to continue the nonclinical and clinical development of its current and future programs. If the Company is able to gain marketing approval for drug candidates that are being developed, it will require significant additional amounts of cash in order to launch and commercialize such drug candidates. In addition, other unanticipated costs may arise. Because the design and outcome of the Company’s planned and anticipated clinical trials is highly uncertain, the Company cannot reasonably estimate the actual amounts necessary to successfully complete the development and commercialization of any drug candidate the Company may develop.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company expects to finance its cash needs through a combination of public or private equity offerings, debt financings, collaborations, strategic alliances, licensing arrangements and/or other marketing or distribution arrangements. In addition, the Company may seek additional capital to take advantage of favorable market conditions or strategic opportunities even if the Company believes it has sufficient funds for its current or future operating plans. Based on the Company’s research and development plans, the Company expects its existing cash, cash equivalents and investments, will enable it to fund its operations for at least 12 months following the date the condensed consolidated financial statements are issued. However, the Company’s operating plan may change as a result of many factors currently unknown, and the Company may need to seek additional funds sooner than planned. Moreover, it is particularly difficult to estimate with certainty the Company’s future expenses given the dynamic nature of its business and the macro-economic environment generally.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company’s ability to raise additional funds depends on financial, economic and other factors, many of which are beyond its control. For example, if there is a disruption of global financial markets, the Company could be unable to access additional capital, which could negatively affect its ability to consummate certain corporate development transactions or other important, beneficial or opportunistic investments. If additional funds are not available to the Company when needed, on terms that are acceptable to the Company, or at all, the Company may be required to: delay, limit, reduce or terminate nonclinical studies, clinical trials or other research and development activities or eliminate one or more of its development programs altogether; or delay, limit, reduce or terminate its efforts to establish manufacturing and sales and marketing capabilities or other activities that may be necessary to commercialize any future approved products, or reduce the Company’s flexibility in developing or maintaining its sales and marketing strategy.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Periodically, the Company maintains deposits in accredited financial institutions in excess of federally insured limits. The Company deposits its cash in financial institutions that it believes have high credit quality and has not experienced any losses on such accounts and does not believe it is exposed to any unusual credit risk beyond the normal credit risk associated with commercial banking relationships. The Company has always maintained a dual banking system to limit its credit and liquidity risk.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
CY2024Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-535900000
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-486800000
CY2024Q3 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
74900000
CY2024Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
79900000
CY2024Q3 us-gaap Stock Issued During Period Shares Reverse Stock Splits
StockIssuedDuringPeriodSharesReverseStockSplits
3300000
CY2024Q3 algs Number Of Fractional Shares Issued In Connection With Reverse Stock Split
NumberOfFractionalSharesIssuedInConnectionWithReverseStockSplit
0
CY2024Q3 us-gaap Stockholders Equity Reverse Stock Split
StockholdersEquityReverseStockSplit
1-for-25
CY2024Q3 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
14116000
CY2023Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
14014000
CY2024Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
11541000
CY2023Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
10755000
CY2024Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2575000
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
3259000
CY2024Q3 us-gaap Depreciation
Depreciation
300000
us-gaap Depreciation
Depreciation
800000
CY2023Q3 us-gaap Depreciation
Depreciation
300000
us-gaap Depreciation
Depreciation
1200000
CY2023Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
0
CY2024Q3 us-gaap Available For Sale Securities Debt Maturities Within One Year Amortized Cost
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost
39559000
CY2024Q3 us-gaap Available For Sale Securities Debt Maturities Within One Year Fair Value
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
39591000
CY2024Q3 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
39559000
CY2024Q3 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
39591000
CY2024Q3 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
500000
us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
1400000
CY2023Q3 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
1000000
us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
2700000
CY2024Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
4407000
CY2023Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
6673000
CY2024Q3 algs Accrued Payables Current
AccruedPayablesCurrent
7007000
CY2023Q4 algs Accrued Payables Current
AccruedPayablesCurrent
7144000
CY2024Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
2747000
CY2023Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
3025000
CY2024Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
14161000
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
16842000
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
12800000
CY2020Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2020Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
us-gaap Common Stock Voting Rights
CommonStockVotingRights
one
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
1257168
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q4 algs Gross Proceeds
GrossProceeds
92100000
CY2023Q4 us-gaap Proceeds From Issuance Of Warrants
ProceedsFromIssuanceOfWarrants
86200000
CY2024Q3 us-gaap Employee Service Share Based Compensation Tax Benefit From Compensation Expense
EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense
0
us-gaap Employee Service Share Based Compensation Tax Benefit From Compensation Expense
EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense
0
CY2023Q3 us-gaap Employee Service Share Based Compensation Tax Benefit From Compensation Expense
EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense
0
us-gaap Employee Service Share Based Compensation Tax Benefit From Compensation Expense
EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense
0
CY2024Q1 algs Number Of Options Exchanged In Connection With Exchange Offer
NumberOfOptionsExchangedInConnectionWithExchangeOffer
155155
CY2024Q1 algs Number Of Replacement Options Granted In Connection With Exchange Offer
NumberOfReplacementOptionsGrantedInConnectionWithExchangeOffer
76147
CY2024Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
3000
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1
ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
P1Y
CY2024Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2043000
CY2023Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3209000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
6747000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
10069000
CY2023Q4 algs Deferred Revenue From Collaborations
DeferredRevenueFromCollaborations
84000
CY2022Q4 algs Deferred Revenue From Collaborations
DeferredRevenueFromCollaborations
8743000
algs Consideration Received
ConsiderationReceived
208000
algs Consideration Received
ConsiderationReceived
679000
algs Contract With Customer Liability Revenue Recognized On Upfront Payment
ContractWithCustomerLiabilityRevenueRecognizedOnUpfrontPayment
-292000
algs Contract With Customer Liability Revenue Recognized On Upfront Payment
ContractWithCustomerLiabilityRevenueRecognizedOnUpfrontPayment
-7329000
CY2024Q3 algs Deferred Revenue From Collaborations
DeferredRevenueFromCollaborations
0
CY2023Q3 algs Deferred Revenue From Collaborations
DeferredRevenueFromCollaborations
2093000
CY2024Q3 algs Contract With Customer Liability Deferred Revenue Recognized On Upfront Payment
ContractWithCustomerLiabilityDeferredRevenueRecognizedOnUpfrontPayment
1300000
CY2023Q3 algs Contract With Customer Liability Deferred Revenue Recognized On Upfront Payment
ContractWithCustomerLiabilityDeferredRevenueRecognizedOnUpfrontPayment
1100000
CY2024Q3 us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
0
CY2023Q3 us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
0
CY2023Q4 algs Deferred Revenue From Customers
DeferredRevenueFromCustomers
1224000
CY2022Q4 algs Deferred Revenue From Customers
DeferredRevenueFromCustomers
700000
algs Deferred Revenue Consideration Received
DeferredRevenueConsiderationReceived
2436000
algs Deferred Revenue Consideration Received
DeferredRevenueConsiderationReceived
6676000
algs Contract With Customer Liability Deferred Revenue Recognized
ContractWithCustomerLiabilityDeferredRevenueRecognized
3005000
algs Contract With Customer Liability Deferred Revenue Recognized
ContractWithCustomerLiabilityDeferredRevenueRecognized
5519000
CY2024Q3 algs Deferred Revenue From Customers
DeferredRevenueFromCustomers
655000
CY2023Q3 algs Deferred Revenue From Customers
DeferredRevenueFromCustomers
1857000
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-19259000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-18041000
us-gaap Net Income Loss
NetIncomeLoss
-49061000
us-gaap Net Income Loss
NetIncomeLoss
-59787000
CY2024Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
6272291
CY2024Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
6272291
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1739847
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
1739847
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
6258706
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
6258706
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1728282
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
1728282
CY2024Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-3.07
CY2024Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-3.07
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-10.37
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-10.37
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-7.84
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-7.84
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-34.59
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-34.59
CY2024Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
2777566
CY2023Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
450643
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
2777566
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
450643
CY2024Q3 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2024Q3 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2024Q3 algs Rule10 B51 Arr Modified Flag
Rule10B51ArrModifiedFlag
false
CY2024Q3 algs Non Rule10 B51 Arr Modified Flag
NonRule10B51ArrModifiedFlag
false
CY2024Q3 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2024Q3 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false

Files In Submission

Name View Source Status
FilingSummary.xml Edgar Link unprocessable
0000950170-24-122371-index-headers.html Edgar Link pending
0000950170-24-122371-index.html Edgar Link pending
0000950170-24-122371.txt Edgar Link pending
0000950170-24-122371-xbrl.zip Edgar Link pending
algs-20240930.htm Edgar Link pending
algs-20240930.xsd Edgar Link pending
algs-ex10_1a.htm Edgar Link pending
algs-ex10_1b.htm Edgar Link pending
algs-ex10_1c.htm Edgar Link pending
algs-ex10_2.htm Edgar Link pending
algs-ex10_2.pdf Edgar Link pending
algs-ex10_3.htm Edgar Link pending
algs-ex31_1.htm Edgar Link pending
algs-ex31_2.htm Edgar Link pending
algs-ex32_1.htm Edgar Link pending
algs-ex32_2.htm Edgar Link pending
algs-ex4_2.htm Edgar Link pending
algs-ex4_2.pdf Edgar Link pending
Financial_Report.xlsx Edgar Link pending
img78852433_0.jpg Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
algs-20240930_htm.xml Edgar Link completed
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending